Julian Baker and Felix Baker

According to a recent filing with the Securities and Exchange Commission, Julian and Felix BakersBaker Bros. Advisors are bullish on Anacor Pharmaceuticals Inc (NASDAQ:ANAC). The filing showed that Baker Bros. owns a passive stake in Anacor, which contains some 4.87 million shares of the company, which represent 11% of the outstanding common stock. This compares with the 4.14 million-share position that Baker Bros. revelead in its last 13F filing (for the end of the third quarter of 2015).

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Baker Bros. Advisors 4,871,046 0 4,871,046 0 4,871,046 11.0%
Baker Bros. Advisors (GP) 4,871,046 0 4,871,046 0 4,871,046 11.0%
Felix J. Baker 4,871,046 0 4,871,046 0 4,871,046 11.0%
Julian C. Baker 4,871,046 0 4,871,046 0 4,871,046 11.0%
Julian Baker And Felix Baker
Julian Baker And Felix Baker
Baker Bros. Advisors

Page 1 of 10 SEC Filing

SCHEDULE 13G

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

Under
the Securities Exchange Act of 1934

(Amendment
No. 2)*

 

Anacor Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
032420101
(CUSIP Number)
January 15, 2016
(Date of Event which Requires Filing of this Statement)

Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

x
Rule 13d-1(b)

 

¨
Rule 13d-1(c)

 

¨
Rule 13d-1(d)

 

*The remainder
of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover
page.

 

The information
required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of
the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act,
but shall be subject to all other provisions of the Act (however, see the Notes).

 

Follow Anacor Pharmaceuticals Inc. (NASDAQ:ANAC)